Evidence map›Paper›PMID 22208981›Full record

ArticleMethods in enzymology2012

Discovery of internalizing antibodies to tumor antigens from phage libraries.

Yu Zhou, James D Marks

Open access · greenAbstract read
In one paragraph

Article in Methods in enzymology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Effectiveness of [European journal of nuclear medicine and molecular imaging · 2024
    Article
  2. Article
  3. Review
  4. Nanoparticle-Based Contrast Agents forContrast media & molecular imaging · 2019
    Review
  5. Discovery of internalizing antibodies to basal breast cancer cells.Protein engineering, design & selection : PEDS · 2018
    Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yu ZhouDepartment of Anesthesia and Perioperative Care, University of California, San Francisco, California, USA.
James D Marks
University of California, San Francisco · US

Funding

Tissue and Outcomes CoreP50CA058207 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRAY, JOE W. · 1992 to 2012
$32.7M
NCI NIH HHS P50 CA058207
6 · The paper itself

Abstract

Phage antibody technology can be used to generate human antibodies to essentially any antigen. Many therapeutic target antigens are cell surface receptors, which can be challenging targets for antibody generation. In addition, for many therapeutic applications, one needs antibodies that not only bind the cell surface receptor but also are internalized into the cell upon binding. This allows use of the antibody to deliver a range of payloads into the cell to achieve a therapeutic effect. In this chapter, we describe how human phage antibody libraries can be selected directly on tumor cell lines to generate antibodies that bind cell surface receptors and which upon binding are rapidly internalized into the cell. Specific protocols show how to (1) directly select cell binding and internalizing antibodies from human phage antibody libraries, (2) screen the phage antibodies in a high-throughput flow cytometry assay for binding to the tumor cell line used for selection, (3) identify the antigen bound by the phage antibody using immunoprecipitation and mass spectrometry, and (4) direct cell binding and internalizing selections to a specific tumor antigen by sequential selection on a tumor cell line followed by selection on yeast displaying the target tumor antigen on the yeast surface.

Indexed as

Antibodies, NeoplasmAntibody AffinityAntibody SpecificityAntigens, NeoplasmBacteriophagesCell Line, TumorDrug DiscoveryEndocytosisEnzyme-Linked Immunosorbent AssayEpitopesFlow CytometryHumansMass SpectrometryMolecular Targeted TherapyNeoplasmsPeptide LibraryAntibodies, NeoplasmAntigens, NeoplasmEpitopesPeptide LibraryRecombinant Fusion ProteinsSingle-Chain Antibodies

Identifiers

PMID22208981
PMCPMC4180867
OpenAlexW167151221

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.